1Chobanian AV,Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure[J]. Hypertension, 2003,42 (6) :1206-1252.
2Mancia G, de Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology(ESC)[J]. Eur heart J, 2007,28 (12) : 1462-1536.
3Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification and control in Western European and the United States [J]. Arch Intern Med,2007,167(2):141-147.
4Neal B,MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs; results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists Collaboration[J]. Lancer, 2000,356(9246) : 1955-1964.
5Calvo C,Gil-Exremera B, Gomez-Fernandez P, et al. Doxazosin GITS versus standard doxazosin in mild to moderate hypertension [J]. Int J Cardiol,2005,101(1) :97-104.
6Os I. Comparison of doxazosin in the treatment of high blood pressure [J]. Int J Clin Pharmaeol Ther,2006,44(3) :99-106.
7Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension[J]. J Cardiovasc Pharmacol, 2003,41(6):866-869.
8Sica DA. Alphal-adrenergic blockers: current usage considerations [J]. J Clin Hypertens ( Greenwich), 2005, 7(12):757-762.
9Pressel Sir,Davis BR, Wright JT, et al. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)[J]. Control Clin Trials,2001,22(1) :29-41.
10AId.HAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TriaI(AI.LHAT)[J]. JAMA,2000,283(15) :1967-1975.
同被引文献11
1Ohta Y, Tsuchihashi T, Onaka U, et al. Usefulness of the alphal-blocker doxazosin as a third-line antihypertensive drug [J]. Hypertens Res,2007,30(4):301-306.
2Alberti C. Apoptosis induction by quinazoline-derived alphal blockers in prostate cancer cells: biomolecular implications and clinical relevance [ J ]. Eur Rev Med Pharmacol Sci, 2007, 11 (1) :59-64.
3Steers WD, Kirby RS. Clinical ease of using doxazosin inBPH patients with and without hypertention[J]. Prostate Cancer Prostatic Dis,2005,8(2) :152-157.
4Rabkin SW, Huff MW, Newman C, et al. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double blind trial: the Alpha Beta Canada Study[J]. Hypertension, 1994,24 (2) : 241-248.
5Grimm RH Jr,Flack JM,Grandits GA,et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group[J]. JAMA,1996,275(20), 1549-1556.
6Glanz M,Garber A J, Mancia G, et al. Meta-analysis of studies using selective alphal-blockers in patients with hypertension and type 2 diabetes[J]. Int J Clin Pratt, 2001,55 (10) : 694- 701.
